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Sexually Dimorphic Regulation of
EET Synthesis and Metabolism:
Roles of Estrogen
An Huang* and Dong Sun
Department of Physiology, New York Medical College, Valhalla, NY, United States
Epoxyeicosatrienoic acids (EETs) are metabolites of arachidonic acid via cytochrome
P450 (CYP)/epoxygenase and are hydrolyzed by soluble epoxide hydrolase (sEH).
Circulating and tissue levels of EETs are controlled by CYP (EET synthesis) and sEH
(EET degradation). Therefore, both increases in CYP activity and decreases in sEH
expression potentiate EET bioavailability, responses that prevail in the female sex as
a function of estrogen. This mini review, based on subtitles listed, briefly summarizes
studies focusing specifically on (1) female-specific potentiation of CYP/epoxygenase
activity to compensate for the endothelial dysfunction; and (2) estrogen-dependent
downregulation of sEH expression, which yields divergent actions in both systemic and
pulmonary circulation, respectively.
Estrogen-Potentiating EET Synthesis in Response to Endothelial Dysfunction:
This section summarizes the current understanding regarding the roles of estrogen
in facilitating EET synthesis in response to endothelial dysfunction. In this regard,
estrogen recruitment of EET-driven signaling serves as a back-up mechanism,
which compensates for NO deficiency to preserve endothelium-dependent vasodilator
responses and maintain normal blood pressure.
Estrogen-Dependent Downregulation of Ephx2/sEH Expression: This section
focuses on molecular mechanisms responsible for the female-specific downregulation
of sEH expression.
Roles of EETs in Systemic Circulation, as a Function of Estrogen-Dependent
Downregulation of sEH: This section summarizes studies conducted on animals that
are either deficient in the Ephx2 gene (sEH-KO) or have been treated with sEH inhibitors
(sEHIs), and exhibit EET-mediated cardiovascular protections in the cerebral, coronary,
skeletal, and splanchnic circulations. In particular, the estrogen-inherent silencing of the
Ephx2 gene duplicates the action of sEH deficiency, yielding comparable adaptations
in attenuated myogenic vasoconstriction, enhanced shear stress-induced vasodilation,
and improved cardiac contractility among female WT mice, male sEH-KO and sEHI-
treated mice.
Roles of Estrogen-Driven EET Production in Pulmonary Circulation: This section
reviews epidemiological and clinical studies that provide the correlation between the
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polymorphism, or mutation of gene(s) involving estrogen metabolism and female
predisposition to pulmonary hypertension, and specifically addresses an intrinsic
causation between the estrogen-dependent downregulation of Ephx2 gene/sEH
expression and female-susceptibility of being pulmonary hypertensive, a topic that has
never been explored before. Additionally, the issue of the “estrogen paradox” in the
incidence and prognosis of pulmonary hypertension is discussed.
Keywords: epoxyeicosatrienoic acids, soluble epoxide hydrolase, sex, estrogen, pulmonary hypertension
INTRODUCTION
It is established that oxidative metabolism of arachidonic acid
through the cyclooxygenase (COX) and lipoxygenase pathways
to biologically activate eicosanoids plays a critical role in the
regulation of pathophysiological processes. To date, a dubbed
“third pathway” of the cytochrome P450 (CYP)/epoxygenase
system has come to the forefront of research with aims to
evaluate the pathophysiological significance of its biologically
active mediators, epoxyeicosatrienoic acids (EETs) (Roman,
2002). EETs possess cardiovascular protective properties in the
systemic circulation via endothelium-derived hyperpolarizing
factor (EDHF)-based vasodilator responses (Archer et al., 2003;
Fleming, 2004; Huang et al., 2004, 2005) to lower blood
pressure in both physiological (Imig, 2012; Sun et al., 2014)
and pathological conditions (Lee et al., 2010; Ma et al., 2013).
The contribution of EETs toward the cardiovascular protection
can be controlled by soluble epoxide hydrolase (sEH), an
enzyme that hydrolyzes EETs to their biologically inactive diols
(dihydroxyeicosatrienoic acids, DHETs) (Newman et al., 2005).
As such, either the potentiation of EET synthesis or the reduction
of EET metabolism is able to increase EET bioavailability, and
therefore, both CYP/epoxygenase and sEH can be therapeutic
targets for cardiovascular diseases. More importantly, both
enzymatic activities are regulated by female hormones/estrogens,
leading to a sex disparity in the presentation of EET-mediated
contributions. In general, beneficial actions of EETs in the
cardiovascular system have been well reviewed (Roman, 2002;
Imig, 2012), however, the sexually dimorphic phenotype, in terms
of female-favorable contributions of EETs is much less addressed.
Thus, this mini-review will summarize studies from the authors’,
as well as others’ laboratories, focusing on (1) female-specific
potentiation of CYP activity to compensate for the endothelial
dysfunction; and (2) estrogen-dependent suppression of sEH
expression that yields divergent actions in the systemic and
pulmonary circulation, respectively.
ESTROGEN-FAVORABLE EET
SYNTHESIS IN RESPONSE TO NITRIC
OXIDE DEFICIENCY
Cytochrome P450 are encoded by a complex superfamily of
genes; they are located in the endoplasmic reticulum and add an
epoxide across one of the four double bonds of arachidonic acid
to produce four EET regiosomers: 5,6-EET, 8,9-EET, 11,12-EET
and 14,15-EET. The CYP2C and CYP2J families are responsible
for the majority of EET generation in mammals (Imig, 2012).
Specifically, CYP2C29 and CYP2C7 are EET synthasase in mouse
and rat vascular endothelium, and express predominantly in
female vessels deficient in NO synthesis (Sun et al., 2010, 2011).
One of rationales for investigating CYP/epoxygenase function
is its compensatory nature, characterized by the fact that
the enzymatic activity and its contribution to the regulation
of cardiovascular function are dampened under physiological
conditions, and become discernible in most instances, only
with endothelial dysfunction, manifested as impaired NO
bioavailability. Therefore, most in vitro studies aiming to
evaluate CYP activities were performed in the presence of
inhibitors of endothelial nitric oxide synthase (eNOS) and
COX. More intriguingly, the CYP/EET-evoked compensatory
action exerts in a female favorable manner, as indicated by the
evidence that in eNOS and COX-1 double knockout (KO) mice,
EET-mediated responses via an EDHF-based event contribute
significantly to the preservation of endothelium-dependent
relaxation, coinciding with normal blood pressure in female
animals (Scotland et al., 2005), with little of this compensation
in their male counterparts that display hypertension, associated
with impaired endothelium-dependent vasodilations (Brandes
et al., 2000). The same responsive pattern was also observed
in the high fructose-induced metabolic syndrome or chronic
insulin-loading animal models, where only hyperinsulinemic
male rats, not females, developed hypertension, even though
both sexes displayed endothelial dysfunction (Galipeau et al.,
2002; Vasudevan et al., 2005); moreover, female ovariectomy
(OV) prevented, and OV with estrogen replacement (OVE)
restored the normotension (Galipeau et al., 2002; Song et al.,
2005). These findings clarify estrogen as an essential player in
the compensation against endothelial dysfunction (deficiency of
NO and/or PGs), via perhaps, recruiting EET/EDHF-dependent
signaling.
In the microcirculation, estrogen, in response to NO
deficiency, affords protection via unveiling the EET/EDHF-
mediated pathway as a back-up mechanism, to maintain normal
microcirculatory resistance. For instance, in female eNOS-
KO mice and female rats treated with L-NAME, estrogen via
activation of estrogen receptors (ERs), evokes a solely EET-
mediated response that fully preserves shear stress-induced
vasodilation (SSID, one of the most important local regulators
in the control of microcirculatory resistance) (Huang et al.,
2001a,b; Wu et al., 2001), reminiscent of a significantly smaller
magnitude of SSID mediated by COX-derived prostaglandins
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(PGs) in male eNOS-KO and L-NAME treated counterparts
(Sun et al., 1999, 2006). Therefore, the female phenotype of
SSID is defined as augmented vasodilator responses mediated
by EETs in an EDHF-based approach, as a function of either
decreased NO, or increased EET bioactivities (Huang and Kaley,
2004), highlighting further, a reverse interaction between the two
endothelial mediators (NO vs. EETs). The female phenotypic
SSID (EET-mediation) can be changed to male phenotype of SSID
(PG mediation) when gonad-intact females are ovariectomized
(Huang et al., 2001b); vice versa, in vitro exposure of male vessels
to a physiological concentration of estrogen enables to elicit a
female phenotype of SSID (Huang et al., 2004). Thus, in the
deficiency/impairment of NO bioactivity, vascular release of EETs
to maintain a normal endothelial sensitivity to shear stress is
dependent of estrogen and occurs via an ER-mediated activation
of a PI3K/Akt pathway to upregulate CYP2C29 and CYP2C7




Mammalian sEH is encoded by the Ephx2 gene and extensively
expressed in multiple organs/tissues including vasculatures;
it converts epoxides to diols by adding water to open the
epoxide, thus inactivating EETs (Harris and Hammock, 2013).
The majority of cardiovascular protective actions elicited by
pharmacological inhibition of sEH activity using sEH inhibitors
(sEHIs) or genetic deletion of the Ephx2 gene have been ascribed
to be due to increases in circulating and tissue/cellular EET levels
(Fang et al., 2004; Deng et al., 2011).
Noteworthily, the estrogen-potentiation of EET production
takes place primarily in the presence of endothelial dysfunction,
whereas estrogen-downregulation of sEH occurs inherently
in physiological conditions. The identification of sexual
dimorphism of sEH was originally reported around the 1980’s,
where sEH activity was found to be remarkably higher in
organs/tissues of male and OV female mice in comparison to
intact females (Denlinger and Vesell, 1989; Pinot et al., 1995),
and further validated by a female-specific downregulation
of sEH expression (Zhang et al., 2009; Kandhi et al., 2015;
Froogh et al., 2016; Qin et al., 2016). This is reminiscent of the
phenomenon known as the “male-specific hypotensive response
to sEH deficiency,” where the deletion of the Ephx2 gene in
male mice elicited a significant reduction in blood pressure, with
minimal hypotensive effects on female mice (Sinal et al., 2000).
We found that KO of the Ephx2 gene (sEH-KO) or treatment
with sEHIs in male mice reduced their blood pressure to the
level comparable to that of wild type (WT) females; in the latter,
disruption of the Ephx2 gene further reduced blood pressure but
with significantly smaller decrement than in male counterparts
(Kandhi et al., 2015; Qin et al., 2015a; 2016; Froogh et al., 2016).
This dose-dependent-like phenomenon implies that females may
heritably possess a mechanism that imitates an action caused
by the deletion of the Ephx2 gene in males, making females
less sensitive to an additional disruption of the gene. By using
in vivo and in vitro models, we demonstrate that estrogen,
through ERs, methylates the Ephx2 gene promoter to silence
its transcriptional activity, a response that involves multiple
transcription factor-driven regulatory signaling (Yang et al.,
2018). This study provides mechanistically based explanations
for the sexually dimorphic expression of sEH and all the
consequences arising therefrom, that will be discussed in the
forthcoming sections.
ROLES OF EETs IN SYSTEMIC
CIRCULATION, AS A FUNCTION OF
ESTROGEN-DEPENDENT
DOWNREGULATION OF SEH
Female-specific downregulation of sEH expression stabilizes
EETs and functionally potentiates EET bioavailability.
In the cerebral circulation, studies using animal models of
ischemia demonstrated that estrogen suppression of sEH was
responsible for the female-favorable protection against cerebral
ischemic damages in an EET-dependent manner (Fairbanks et al.,
2012; Davis et al., 2013).
In the coronary circulation, our laboratories have provided
evidence indicating sex-different adaptation of cardiac
performance, by conducting experiments on Langendorff-
perfusion preparations. In physiological conditions, challenged
with same increases in preload, female hearts displayed
significantly greater cardiac contractility, associated with
enhanced coronary blood flow and lower vascular resistance
compared to male hearts (Qin et al., 2016). Isolated coronary
arteries from female hearts exhibited significantly attenuated
pressure-induced myogenic vasoconstriction compared to
male arteries, responses that were prevented by 14,15-EEZE (a
putative inhibitor of EETs) (Froogh et al., 2016; Qin et al., 2016).
These female-specific adaptations were also observed in male
sEH-KO mice, implying that estrogen downregulation of sEH
duplicates actions of Ephx2 deletion, yielding identical patterns
of attenuated coronary myogenic responses, enhanced coronary
perfusion and improved cardiac contractility, along with similar
cardiac EET metabolic profiles (a great ratio of EETs/DHETs)
among female WT, male sEH-KO mice and male WT mice
treated with sEHIs (Sun et al., 2014; Qin et al., 2015b). In
pathological conditions, Seubert’s group using cardiac ischemia
models provided strong evidence indicating an EET-driven
protection against ischemia/reperfusion-induced cardiac injury
in sEH deficient animals (Chaudhary et al., 2009).
In the skeletal muscle and splanchnic circulations, isolated
arterioles from female WT mice exhibited significantly greater
magnitude of EET-mediated SSID, accompanied with attenuated
arteriolar tone than those of male WT controls, responses that
were also elicited in vessels isolated from male sEH-KO mice (Sun
et al., 2014; Qin et al., 2015a).
Collectively, the evidence of estrogen-dependent suppression
of Ephx2/sEH expression provides a novel mechanistic
explanation, in addition to the estrogen potentiation of
NO-mediated responses (Huang and Kaley, 2004), for the
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better cardiac performance and lower incidence of ischemic
cardiovascular diseases in women than men.
ROLES OF ESTROGEN-DRIVEN EET
PRODUCTION IN PULMONARY
CIRCULATION
The systemic circulation is benefited from EETs, which then,
creates a question as to whether the increase in pulmonary
EETs is a “friend or foe?” In addition to the typical feature
of low oxygenated blood in the pulmonary artery (PA), there
are other two unique features in the pulmonary circulation
that differ from the systemic circulation: (1) hypoxia pulmonary
vasoconstriction (HPV) (Sylvester et al., 2012) that is reminiscent
of hypoxia-induced vasodilation in systemic vasculatures (Busse
et al., 1983) and (2) EET-induced pulmonary vasoconstriction
via perhaps, depolarizing PA smooth muscle cells (SMC) (Zhu
et al., 2000; Kandhi et al., 2016) in contrast to EET-induced
vasodilation in systemic vasculatures via hyperpolarizing vascular
SMC. Although currently, there is no specific explanation for the
divergent responsiveness to hypoxia and EETs in the pulmonary
circulation, both features seem to be relevant to estrogens, which
therefore, sheds light upon the categorization of pulmonary
hypertension (PH) as a disease with female-specific prevalence
(Miller, 2012).
Thus, human studies show a female to male ratio of 4.3:1
among the total PH patients (Walker et al., 2006), and 4.1:1 in
the idiopathic PH (IPAH) subcategory (Badesch et al., 2010).
This sexual dimorphism in PH is evoked at least in part, by
estrogen, as evidenced by a high PH prevalence in women who
have taken oral contraceptives (Kleiger et al., 1976), received
hormone replacement therapy (Sweeney and Voelkel, 2009) or
had enhanced aromatase activity (Roberts et al., 2009). Also, male
IPAH patients exist with significantly higher plasma estrogen
levels, or a greater ratio of estrogen to testosterone than healthy
males (Wu et al., 2018).
Clinical studies provide correlations between the
polymorphism of gene(s) involving estrogen metabolisms
and the female predisposition to PH (Austin et al., 2009). In
general, the mutation in the BMPR2 gene turns out to be one of
the most important genetic-based alterations responsible for the
sex-bias in IPAH (Morse et al., 2001; Austin et al., 2013; Dempsie
et al., 2011; White et al., 2011), as the penetrance of PH among
BMPR2 mutation carriers shows a 42% penetrance in females
vs. 14% in males (Larkin et al., 2012). Female BMPR2 mutation
carriers with PH exhibit a ten-fold reduction in CYP1B1 gene
expression (West et al., 2008; White et al., 2012), followed
by altered estrogen metabolism, manifested by a significantly
lower ratio of 2-OHE1/2 to 16α-OHE1 (Austin et al., 2009). This
estrogen dysmetabolism shifts the balance away from 2-OHE1/2-
induced anti-mitogenic effects toward 16α-OHE1-stimulated
pulmonary mitogenic and genotoxic pathways (Austin et al.,
2013). Direct binding of ERα to the promoter of BMPR2 gene
silences its expression, which disrupts downstream signaling of
bone morphogenetic protein-dependent ligand binding, kinase
activation and heteromeric dimer formation etc. (Lane et al.,
2000; Austin et al., 2012; Johansen et al., 2016).
To date, there is little attention paid to the intrinsic causation
between the estrogen-driven physiological downregulation
of Ephx2 gene/sEH and female-susceptibility to be pulmonary
hypertensive, a topic that is being investigated in our laboratories.
As reported, increases in pulmonary EETs caused by estrogen
downregulation of sEH, knockdown of sEH and treatment
with sEHIs propel HPV and promote elevation of PA pressure
in response to acute hypoxia (Keseru et al., 2010; Kandhi
et al., 2015, 2017). Underlying mechanisms responsible for
the EET-dependent potentiation of HPV and hypoxia-induced
pulmonary hypertension (HPH) remain elusive; however, roles
of vasoconstrictor prostanoids and Rho kinase in this process
have emerged, as shown that enhanced hypoxic responses
were prevented by 14,15-EEZE, and by inhibition of COXs
and Rho kinase, respectively (Keseru et al., 2008; Kandhi
et al., 2017). Additionally, the membrane translocation of a
TRPC6-V5 fusion protein within PASMC was sensitive to
14,15-EEZE, and hypoxia-induced EET-mediated increases in
pulmonary pressure failed to be elicited in mouse lungs that were
deficient in TRPC6 (Keseru et al., 2008). Thus, the interaction
among estrogen/ERs, sEH/EETs and hypoxia/TRPC6/Rho
kinase/PGs works reciprocally, forming a feedback loop in
a pattern of cause and result for one another, to elevate PA
pressure.
Furthermore, the sex disparity during the development of
HPH was evaluated by using radio-telemetry to dynamically
monitor changes in rat PA pressure. Figure 1 shows that under
a comparable basal/normoxic PA pressure, male and female rats
displayed a time-dependent elevation of PA pressure in response
to hypoxia, which, however, occurred earlier accompanied with
greater magnitude in females than males, revealing female
oversensitivity to hypoxia. This hypoxic responsiveness in female
rats was also observed in sEHI-treated male rats, indicating the
role of EETs in the event. Noteworthily, during the process of
FIGURE 1 | Changes in pulmonary artery (PA) pressure before (normoxia) and
after exposure of male (blue) and female (red) mice, and male rats treated with
TPPU (green) to hypoxia for 8 days.
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HPH development, hypoxia per se, enables to stimulate EET
synthesis (Michaelis et al., 2005) and suppress sEH expression
in a sex-independent manner (Petruzzelli et al., 1992), which
exacerbate EET-mediated HPV in both genders. Alternatively,
when PH is ultimately established, female patients paradoxically
exhibited less impairment in right ventricle (RV) function,
indicating better PH prognosis compared to males (Mair et al.,
2014).
A lack of consensus regarding to roles of estrogen in PH is
presumably, due to the presence of the “estrogen paradox” that
is characterized by divergent actions (detrimental and beneficial)
of estrogens in the incidence and prognosis of PH (Lahm et al.,
2014). Figure 2 interprets “estrogen paradox” to mean that
Ephx2/sEH and CYP are intimately involved in the pathogenesis
of HPH, via being targeted and dysregulated by estrogen and
hypoxia to increase pulmonary EET bioavailability. Female PAs
are capable of maintaining a normal pressure in response to
physiological increases in pulmonary EETs due to the presence
of compensatory balancing mechanisms such as estrogen-
upregulation of eNOS/NO, but bear hyper-responsiveness to
acquired pathological challenges such as hypoxia or altered
estrogen metabolism, leading to the female susceptibility to
PH. Alternatively, all types of PH regardless of their specific
etiologies, undergo/share a common progressive process that
involves multiple pathological alterations including but not
limited to, the endothelial dysfunction, enhanced oxidative
stress and inflammation, vascular remodeling and formation of
occlusive lesions, leading to RV hypertrophy and dysfunction,
and eventually right heart failure (Rabinovitch, 2012), whereas,
all of these pathological alterations can be challenged against by
estrogens. For instance, in sugen-hypoxia (SuHx-HP)-induced
PH, estrogen improves RV function via inotropic effects on
myocardium (Liu et al., 2014) and restoration of conduit PA
compliance (Liu et al., 2015). In monocrotaline (MCT)-induced
PH, estrogen prevents MCT-induced impairment of antioxidant
capacity to preserve myocardial function (Bal et al., 2013). This
points to a non-specific pattern of estrogen-driven improvement
of PH prognosis, which is neither selectively triggered by a
specific model of PH, nor does it direct particular target(s),
and provides explanations for the better prognosis with higher
survival rate in female than male PH patients.
Currently, clinical trials designed to evaluate the protection
of sEHIs if any, for patients with chronic obstructive pulmonary
diseases (COPD) reveled that GSK alleviated endothelial
dysfunction in COPD patients (Lazaar et al., 2016; Yang
et al., 2017). Since HPH, as well as COPD, is associated with
downregulation of sEH and upregulation of EET production,
the improvement of endothelial function elicited by GKS in
COPD patents may not be purely, mediated by the inhibition
of sEH per se, but rather by alternative pathways. Indeed, in
FIGURE 2 | During the process of switch from a physiologically based downregulation of sEH by estrogen/estrogen receptors (ERs) to the pathological development
of pulmonary hypertension (PH), multiple pathological stimuli operate in concert, to interrupt the normal physiological balance, tipping the balance toward PA
constrictor axis. As indicated, pathological increases in EETs, as a function of upregulation of EET syntheses (CYP) or suppression of Ephx2/sEH elicit PA
constriction and promote actions of constrictor prostaglandins (PGs), resulting in an EET-potentiation of PH, which eventually impairs right ventricular (RV) function.
On the other hand, RV dysfunction is alleviated by estrogen. The systemic circulation is also benefited by estrogen- and EET-mediated protections. Arrow-head
indicates promotion. Flat-head indicates suppression. Estrogen-promotion of incidence and -improvement of prognosis of PH are demarcated by lines designated in
red and green respectively.
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addition to targeting sEH, sEHIs are capable of binding with
other enzymes due to the presence of multi-target ligands. For
instance, PTUPB is a tight COX-2 binder (Hwang et al., 2018)
and TPPU selectively inhibits p38β kinase to block downstream-
located NF-κB-dependent signaling (Liang et al., 2018). As
such, pharmacological inhibition of sEH to stabilize EETs may
instigate PA vasoconstriction but somehow, mitigate pathological
progression in the pulmonary circulation.
SUMMARY AND PERSPECTIVES
We briefly summarized the pathophysiological significance of
potentiating EET production and/or inhibiting EET hydrolysis,
as a function of estrogen, in the regulation of systemic and
pulmonary circulations. In the systemic circulation, increases
in EETs afford better cardiovascular performance and lower
incidence of ischemic diseases in women. In the pulmonary
circulation, clinical development of PH appears to require
“two hits” that can be triggered by either genetics (sex and
gene polymorphisms), environmental factors (hypoxia and sex
hormone dysmetabolism), or both (female with hypoxia). Thus,
from a pros and cons point of view, targeting CYP and sEH
may prove to be a double-edged sword with beneficial and
adverse effects on systemic and pulmonary circulatory systems;
this brings concerns surrounding the use of sEHIs as therapeutic
regimens, or the consideration of sEHI-related clinical trials in
female populations who bear hyper-responsiveness to acquired
pathological insults (as second hits) to the respiratory system.
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